Ascendis Health Limited saw associates of two of its directors, Carl Neethling and Theunis de Bruyn, engage in on-market transactions to acquire shares. The dealings were conducted in accordance with the JSE Limited Listings Requirements.
On 23 June 2023, Carl Neethling, a director of Ascendis Health Limited, purchased 192,854 ordinary shares at a price of 61.37 cents per security, amounting to a total value of R118,354.50. This transaction was carried out through Neethling’s associate, ACN Capital (Pty) Ltd. Neethling has an indirect, beneficial interest in the purchase, as he is the ultimate controlling shareholder of ACN Capital (Pty) Ltd.
Simultaneously, Theunis de Bruyn, also a director of Ascendis Health Limited, acquired 192,854 ordinary shares at the same price of 61.37 cents per security, totaling R118,354.50. De Bruyn’s purchase was made through his associate, Calibre Investment Holdings (Pty) Ltd. He holds an indirect, beneficial interest in the transaction due to his position as a director and shareholder of Calibre Investment Holdings (Pty) Ltd.
The acquisitions by the directors’ associates were granted clearance in accordance with paragraph 3.66 of the JSE Limited Listings Requirements.
Ascendis Health Limited is a highly regarded healthcare company operating in South Africa, offering a comprehensive range of healthcare products and services, including pharmaceuticals, consumer health goods, and medical devices. The recent share acquisitions by the associates of the directors exemplify their confidence in Ascendis Health’s future prospects and investment potential.
The management of Ascendis Health believes that these transactions further align the interests of the directors and their associates with the company’s success. By increasing their indirect beneficial ownership, the directors and their associates demonstrate their commitment to Ascendis Health’s long-term growth strategy.
This website uses cookies.
